Navigation Links
T2 and collaborators announce discovery of novel clot structure biology enabled by T2HemoStat
Date:1/9/2014

Lexington, MA, January 9, 2014 T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that scientists from the University of Pennsylvania and T2 Biosystems have published a paper in Blood describing novel clot structure biology detected while testing T2 Bio's T2HemoStat. T2HemoStat is an innovative diagnostic tool for assessing blood clotting, platelet function, fibrinolytic activity and hematocrit measurements from a fingerstick blood sample in about 15 minutes. T2HemoStat uniquely detects millions of data points during a blood coagulation cascade. Researchers at the University of Pennsylvania, utilizing T2HemoStat, detected a signature of a novel clot structure, never before described in scientific literature. This clot structure involves a conformational change in red blood cell structure, termed polyhedrocytes. The presence of these structures could make stroke and heart attack victims less responsive to medications.

Blood clots are made up of fibrin, platelets and erythrocytes. Before now, little was known about the internal structure of contracted clots or the role that erythrocytes play in the contraction process. T2HemoStat is the first diagnostic method to enable the detection of this unique clot structure where erythrocytes are closely packed as polyhedra (polyhedrocytes) to form a seemingly impermeable barrier. This barrier means that these clot structures may be less susceptible to certain medications, called fibrinolytics, used to break up blood clots in the treatment of heart attacks and strokes.

"Physicians treating the millions of patients at risk for thrombosis and bleeding, including after surgery or trauma, are in need of a more convenient method to provide up to the minute results of key hemostatic parameters," commented co-author Douglas B. Cines, MD, Professor of Pathology and Laboratory Medicine and Director of the Special Coagulation Laboratory, Perelman School of Medicine at the University of Pennsylvania.

"Polyhedrocytes are likely to be central to preventing bleeding and promoting blood flow after damage to blood vessels has begun to heal. However, when the process goes awry, in the case of clotting diseases, these tightly packed erythrocytes present a challenge to clot-busting thrombolytic agents, as they are more resistant to fibrinolysis," said co-author John W. Weisel, Ph.D., Professor of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania.

"This landmark publication demonstrates that T2HemoStat can be an important tool to identify biomarkers for companion diagnostics or new drug development, in this case, specifically targeted at highly contracted clots containing polyhedrocytes," added Tom Lowery, Ph.D., Chief Scientific Officer, T2 Biosystems and co-author in the study. "Furthermore, this new finding enabled by T2HemoStat demonstrates the power and versatility of our T2MR technology both in the research setting and as it can relate to meaningful clinical advances."

The paper, entitled "Clot contraction: compression of erythrocytes into tightly packed polyhedra and redistribution of platelets and fibrin", was authored by Douglas B. Cines, Tatiana Lebedeva, Chandrasekaran Nagaswami, Vincent Hayes, Walter Massefski, Rustem I. Litvinov, Lubica Rauova, Thomas J. Lowery and John W. Weisel. After identification of samples and sample conditions that form this novel clot with T2MR, the group used scanning electron and optical microscopy to determine that contracted clots consist of a meshwork of fibrin and platelet aggregates on the exterior of the clot with a closely-packed, tessellated array of compressed polyhedral erythrocytes (polyhedrocytes) on the interior.

This phenomenon was observable both in vivo and in vitro in humans and mice, and is likely caused by the force that the fibrin and platelets place upon the erythrocytes, as centrifugation of erythrocytes in the absence of these components also generated the polyhedral structure. These results demonstrate how contracted clots form an impermeable barrier important for hemostasis and wound healing and help explain how fibrinolysis is greatly slowed as clots contract.


'/>"/>

Contact: Kari Watson
kwatson@macbiocom.com
781-235-3606
MacDougall Biomedical Communications, Inc.
Source:Eurekalert

Related biology news :

1. WHOI researchers, collaborators receive $1.4 million grant to study life in oceans greatest depths
2. Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
3. MARC travel awards announced for the APS 2014 Professional Skills Training Course
4. CROS NT Ltd Announces Acquisition of MDSL International Ltd.
5. FacialNetwork.com Announces Beta Release Of "NameTag" The First Real-Time Facial Recognition App For Google Glass
6. HGH Supplements Information Website HGH.us.com Announces New Discounts on Sytropin and Genf20 Plus
7. BBSRC announces £10M of funding for advanced scientific equipment
8. Life Sciences Discovery Fund announces R&D grants
9. Genetics Society of America announces recipients of spring 2014 DeLill Nasser Award
10. CROS NT Ltd Announces Appointment of Andrew MacGarvey as CEO
11. Biophysical Society announces speakers for Future of Biophysics Burroughs Wellcome Fund Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... On Monday, the Department of Homeland Security (DHS) issued ... the Biometric Exit Program. The Request for Information (RFI), ... that CBP intends to add biometrics to confirm when ... , in order to deter visa overstays, to ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/15/2016)... , June 15, 2016 ... market report titled "Gesture Recognition Market by Application Market - Global ... 2016 - 2024". According to the report, the  global ... billion in 2015 and is estimated to grow ... 48.56 billion by 2024.  Increasing application ...
(Date:6/3/2016)... Das DOTM (Department ... hat ein 44 Millionen $-Projekt ... einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an Decatur ... Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale Anbieter ... aber Decatur wurde als konformste und innovativste ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... CLEVELAND , June 27, 2016  Global ... average 4.6 percent through 2020 to $7.2 billion.  ... (food and beverages, cleaning products, biofuel production, animal ... and biotechnology, diagnostics, and biocatalysts). Food and beverages ... gains driven by increasing consumption of products containing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: